Adicet Bio Shareholders Approve Flexible Reverse Stock Split

Adicet Bio ( (ACET) ) just unveiled an announcement.

On December 19, 2025, Adicet Bio, Inc. held a Special Meeting of Stockholders at which investors approved an amendment to the company’s Restated Certificate of Incorporation authorizing a reverse stock split of its common shares at a ratio between one-for-five and one-for-thirty, with the exact ratio to be determined at the board’s discretion. The strong approval, with more than 111 million votes in favor and only about 2.8 million against, gave management flexibility to reduce the number of outstanding shares, a step commonly used to support compliance with stock exchange listing standards or improve the perceived value of the stock, and rendered unnecessary a contingent proposal to adjourn the meeting for further proxy solicitation.

The most recent analyst rating on (ACET) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Adicet Bio stock, see the ACET Stock Forecast page.

Spark’s Take on ACET Stock

According to Spark, TipRanks’ AI Analyst, ACET is a Underperform.

Adicet Bio faces significant financial challenges and technical weaknesses, with no revenue and ongoing losses as critical concerns. The poor valuation further impacts the stock’s appeal. While the new board appointment is positive, it does not mitigate the substantial risks present in the company’s financials and market performance.

To see Spark’s full report on ACET stock, click here.

More about Adicet Bio

Adicet Bio, Inc. is a biotechnology company focused on developing innovative therapies, operating as a Delaware corporation and listed in U.S. capital markets, with its common stock subject to typical exchange listing and corporate governance requirements.

Average Trading Volume: 2,369,646

Technical Sentiment Signal: Sell

Current Market Cap: $72.08M

For a thorough assessment of ACET stock, go to TipRanks’ Stock Analysis page.